Genmab — Maj 2018
-
FDA vil sætte fart i udvikling af gen- og celleterapier: Starter med hæmofili
Det amerikanske lægemiddelagentur vil gøre det lettere for udviklere af genterapier og celleterapier at få godkendt deres produkter. Til at begynde med sætter man fokus på hæmofili-området, hvor to eksperimentelle genterapier netop har vist lovende kliniske resultater. Det kan betyde et øget pres på Novo Nordisk.
(medwatch.dk)
-
Daratumumab and Elotuzumab: Potential mAb Therapies for Multiple Myeloma https://www.cancertherapyadvisor.com/multiple-myeloma/multiple-myeloma-daratumumab-elotuzumab-potential-mab-therapy/article/768206/
-
Genmab (GMXAY) Presents At 2018 UBS Global Healthcare Conference - Slideshow - https://seekingalpha.com/article/4176638-genmab-gmxay-presents-2018-ubs-global-healthcare-conference-slideshow
-
Sometimes things happen fast: "This may be an error (ct.gov can sometimes experience incorrect updates.
Let me ask my team here and if you don’t hear from me it is an error. Otherwise I will come back to you.Both NVS and Genmab are still anticipating data readouts in 2019.
Yours Rachel"
I'll inform the chat if it's not an error. -
God morgen.
-
God morgen
)Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind